International Flavors & Fragrances
IFF
$76.26
-1.31%
International Flavors & Fragrances (IFF) is the world's largest specialty ingredients producer, supplying flavors, fragrances, health and bioscience ingredients, and food texturants to the food, beverage, personal care, and pharmaceutical industries. As a global market leader in flavors and fragrances, and a top player in probiotics and enzymes, IFF differentiates itself through its proprietary formulations and deep customer partnerships. The current investor narrative centers on the planned divestiture of its Food Ingredients segment (expected to close in 2027), which is seen as a catalyst to streamline operations and reduce debt, while the company navigates a mixed demand environment and works to restore margin growth after a period of earnings volatility.…
IFF
International Flavors & Fragrances
$76.26
Related headlines
Investment Opinion: Should I buy IFF Today?
Rating: Buy. Thesis: IFF is a compelling turnaround play with improving profitability, a clear divestiture catalyst, and strong analyst support, offering 16.6% upside to the average target of $91.21. The stock is attractively valued on forward earnings (P/E 16.3x) and near the low end of its historical P/S range, providing a margin of safety.
Supporting Evidence: The primary valuation metric, P/S of 1.58x, is below the 5-year average of ~2.5x, indicating a discount to history. Revenue growth is negative (-3.6% YoY), but the trajectory is stabilizing, and Q1 2026 gross margin improved to 37.1% from 36.4% a year ago. Free cash flow of $398M TTM supports the dividend yield of 2.37%. The analyst consensus is Buy with a mean target of $91.21, implying 16.6% upside, and the forward P/E of 16.3x is reasonable for a company expected to earn $5.32 EPS next year.
Risks & Conditions: The biggest risks are continued revenue contraction and failure to sustain margin improvement. This Buy rating would be downgraded to Hold if revenue growth remains negative for two consecutive quarters or if operating margin falls below 8%. It would be upgraded to Strong Buy if the divestiture is announced with favorable terms or if revenue turns positive. Overall, IFF appears fairly valued relative to its history but slightly overvalued versus industry peers; however, the turnaround potential justifies the premium.
Sign up to view all
IFF 12-Month Price Forecast
The AI assessment is cautiously bullish on IFF. The improving profitability trajectory (operating margin up from -31.8% to 10.2%) and strong analyst support (Buy consensus, 16.6% upside) are positive signals. However, the ongoing revenue decline (-3.6% YoY) and premium valuation versus peers (P/S 1.58x vs 1.2x) introduce uncertainty. The base case of gradual improvement to the average target of $91.21 is the most probable outcome, but the bull case could materialize if the divestiture accelerates. The stance would be upgraded to high confidence if revenue turns positive, and downgraded to neutral if margins fail to expand.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $91.54 and implied upside of +20.0% versus the current price.
Average Target
$91.54
0 analysts
Implied Upside
+20.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$71 - $105
Analyst target range
IFF is covered by 18 analysts, with a consensus recommendation of 'Buy' (mean rating 1.65 on a 1-5 scale where 1 is Strong Buy). The average target price is $91.21, implying approximately +16.6% upside from the current price of $78.20. The distribution shows a bullish tilt, with no sell ratings and a strong buy consensus, reflecting confidence in the company's strategic direction and earnings recovery. The target price range spans from a low of $71.00 to a high of $105.00. The high target of $105 assumes successful execution of the Food Ingredients divestiture, margin expansion, and renewed growth in Health & Biosciences, potentially driving multiple expansion. The low target of $71.00 factors in continued revenue declines, slower-than-expected margin recovery, or execution risks related to the divestiture. Recent ratings from major firms (Morgan Stanley, Argus, Citigroup, Barclays, JP Morgan, Oppenheimer) have all been positive (Overweight/Buy/Outperform) and reaffirmed in recent months, indicating strong institutional conviction. The relatively wide spread between low and high targets ($34) suggests moderate uncertainty, but the consistent bullish stance from top-tier banks lends credibility to the positive outlook.
Bulls vs Bears: IFF Investment Factors
IFF presents a balanced risk/reward profile. The bull case is anchored by a strong analyst consensus (Buy, 16.6% upside), improving profitability metrics (operating margin recovery to 10.2%), and a strategic divestiture catalyst that could simplify the business and unlock value. The bear case centers on ongoing revenue contraction (-3.6% YoY), negative ROE (-2.6%), and a premium valuation relative to industry peers (P/S 1.58x vs 1.2x). The single most important tension is whether the company can sustain its margin recovery and return to revenue growth before the divestiture closes in 2027. If it does, the stock could re-rate higher; if not, the premium valuation may compress. Currently, the evidence slightly favors the bulls given the strong institutional backing and improving fundamentals, but the revenue trend remains a critical watchpoint.
Bullish
- Strong analyst consensus and upside: 18 analysts rate IFF a Buy with a mean target of $91.21, implying 16.6% upside from $78.20. No sell ratings and consistent Overweight ratings from major banks (Morgan Stanley, Citigroup) indicate institutional confidence in the turnaround.
- Divestiture catalyst for simplification: The planned divestiture of the Food Ingredients segment (expected 2027) will streamline operations and reduce debt. This segment generated $839M in Q1 2026 revenue (30.6% of total), and its sale could unlock value by focusing on higher-margin Taste, Scent, and Health & Biosciences.
- Improving profitability trajectory: Q1 2026 operating margin improved to 10.2% from -31.8% a year ago, and gross margin rose to 37.1% from 36.4%. Net income swung from a -$1.018B loss to a $169M profit, demonstrating operational recovery.
- Attractive valuation on forward earnings: Forward P/E of 16.3x is reasonable given the expected EPS recovery to $5.32. The P/S ratio of 1.58x is near the low end of its 5-year range (1.0x-12.7x), suggesting the market is not pricing in the full turnaround potential.
Bearish
- Revenue decline signals demand weakness: Q1 2026 revenue fell 3.6% YoY to $2.741B, following a mixed pattern. This top-line contraction suggests ongoing demand softness in key end markets, which could delay the earnings recovery priced into the stock.
- Negative ROE and inconsistent profitability: ROE is -2.6% and TTM net margin is -3.3%, indicating the company has not consistently generated shareholder value. Despite Q1 improvement, the trailing twelve months still show a net loss, highlighting earnings volatility.
- Premium valuation versus industry peers: IFF's P/S ratio of 1.58x is 32% above the specialty chemicals industry average of 1.2x. This premium may be unjustified if the revenue decline continues or margin recovery stalls, leaving the stock vulnerable to multiple compression.
- Execution risk on divestiture and debt: The Food Ingredients divestiture is not expected to close until 2027, creating a prolonged period of uncertainty. Debt-to-equity of 0.47 is manageable but interest expense of $44M in Q1 2026 still weighs on earnings, and any delay could pressure the balance sheet.
IFF Technical Analysis
IFF's 1-year price change of +4.2% reflects a modest uptrend, but the stock is trading at $78.20, which is 92.6% of its 52-week range ($59.14–$84.45). This positioning near the upper end of the range suggests positive momentum, though not yet at overbought extremes, indicating room for further upside if catalysts materialize. The stock's beta of 0.94 implies slightly lower volatility than the market, making it a relatively defensive holding within the specialty chemicals space. Over the past 1 month, IFF has gained 2.8%, while the 3-month change is +3.1%, showing steady but decelerating momentum compared to the 6-month gain of 9.1%. The 1-month relative strength versus SPY is +2.5%, indicating outperformance, but the 1-year relative strength is -14.1%, highlighting that the stock has lagged the broader market over the longer term. This divergence suggests that recent positive momentum may be a reversal attempt rather than a sustained trend shift. The 52-week low of $59.14 provides strong support, while the 52-week high of $84.45 acts as immediate resistance. A breakout above $84.45 would signal a new uptrend and could attract momentum buyers, while a breakdown below $59.14 would likely indicate a bearish continuation. With a beta of 0.94, IFF's volatility is in line with the market, meaning it offers no significant amplification of market moves, which may appeal to risk-averse investors.
Beta
0.94
0.94x market volatility
Max Drawdown
-23.1%
Largest decline past year
52-Week Range
$59-$84
Price range past year
Annual Return
+0.0%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +0.2% |
| 3m | +7.2% | +5.2% |
| 6m | +5.7% | +8.6% |
| 1y | +0.0% | +19.0% |
| ytd | +12.1% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
IFF's revenue trajectory shows a slight decline, with Q1 2026 revenue of $2.741 billion down 3.6% year-over-year, following a mixed pattern: Q4 2025 revenue was $2.589 billion (down from Q1 2025's $2.843 billion). The company's four segments—Taste ($656M), Scent ($651M), Health & Biosciences ($595M), and Food Ingredients ($839M)—show a relatively balanced portfolio, though Food Ingredients is the largest and slated for divestiture. The revenue decline reflects ongoing demand softness in certain end markets, but the planned divestiture could simplify the business and improve focus on higher-growth areas like Health & Biosciences. Profitability has been volatile: Q1 2026 net income was $169 million (net margin 6.2%), a sharp recovery from the loss in Q1 2025 (-$1.018 billion), but gross margin improved to 37.1% from 36.4% a year ago. The trailing twelve-month net margin is -3.3%, indicating that the company is still working toward consistent profitability. Operating margin in Q1 2026 was 10.2%, up from -31.8% in Q1 2025, showing significant operational improvement, but still below the industry average for specialty chemicals (typically 12-15%). IFF's balance sheet shows manageable leverage with a debt-to-equity ratio of 0.47 and a current ratio of 1.42, indicating adequate liquidity. Free cash flow for Q1 2026 was $92 million, and trailing twelve-month FCF was $398 million, providing some cushion for debt service and dividends. However, ROE is negative at -2.6%, reflecting the impact of past losses on equity. The company's ability to generate positive FCF is a positive sign, but the negative ROE suggests that shareholder value creation remains challenged.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
-3.6%
YoY Comparison
Gross Margin
37.1%
Latest Quarter
Free Cash Flow
$398000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Since IFF's trailing net income is negative (TTM net margin -3.3%), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 1.58x, while the forward PE (based on positive expected earnings) is 16.3x. The gap between the trailing loss and forward PE implies the market expects a significant earnings recovery, which is consistent with the analyst consensus EPS estimate of $5.32 for the next fiscal year. Compared to the industry average PS ratio for specialty chemicals (approximately 1.2x), IFF trades at a 32% premium, reflecting its market leadership and diversified portfolio. However, this premium may be justified by the company's scale and the potential for margin expansion post-divestiture. Historically, IFF's PS ratio has ranged from about 1.0x to 12.7x over the past five years. The current 1.58x is near the lower end of that range, suggesting the stock is relatively cheap compared to its own history. This low multiple could indicate that the market is discounting the company's near-term challenges, but it also presents a potential value opportunity if the turnaround gains traction.
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~340x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IFF's primary financial risk is its inconsistent profitability. While Q1 2026 showed a net income of $169M, the trailing twelve-month net margin is -3.3% and ROE is -2.6%, indicating that past losses have eroded equity. The company carries $44M in quarterly interest expense against a debt-to-equity ratio of 0.47, which is manageable but still a drag on earnings. Revenue concentration is moderate, with the largest segment (Food Ingredients) accounting for 30.6% of sales, but this segment is slated for divestiture, creating execution risk. Free cash flow of $92M in Q1 2026 and $398M TTM provides some cushion, but negative ROE suggests value creation remains challenged.
Market & Competitive Risks: IFF trades at a P/S of 1.58x, a 32% premium to the specialty chemicals industry average of 1.2x, making it vulnerable to multiple compression if growth disappoints. The stock's beta of 0.94 implies lower market correlation, but its 1-year relative strength of -14.1% versus SPY highlights persistent underperformance. Competitive risks include potential loss of market share in flavors and fragrances to smaller, more agile players. Regulatory risks are moderate, but any changes in food safety or environmental regulations could impact costs. The recent Investing.com article noted IFF as an oversold S&P 500 stock with rebound potential, but macro headwinds like high interest rates could continue to pressure growth stocks.
Worst-Case Scenario: If revenue continues to decline, margin recovery stalls, and the Food Ingredients divestiture faces delays or unfavorable terms, IFF could see its stock fall to the 52-week low of $59.14, representing a -24.4% decline from the current price of $78.20. This scenario would likely involve analyst downgrades and a re-rating to a P/S closer to 1.0x, the low end of its historical range. The maximum drawdown over the past year was -24.01%, consistent with this downside. In a severe recession, the stock could fall further, but the 52-week low provides a reasonable worst-case estimate.
FAQ
The key risks are: 1) Financial risk: inconsistent profitability with a TTM net margin of -3.3% and negative ROE of -2.6%, meaning the company has not consistently generated shareholder value. 2) Revenue risk: Q1 2026 revenue declined 3.6% YoY, and if this trend continues, it could delay the earnings recovery and compress the valuation multiple. 3) Execution risk: the planned Food Ingredients divestiture (expected 2027) may face delays or unfavorable terms, creating uncertainty. 4) Macro risk: with a beta of 0.94, IFF is slightly less volatile than the market, but a recession could reduce demand for specialty ingredients. The most severe risk is a prolonged revenue decline combined with margin compression, which could drive the stock to the 52-week low of $59.14 (-24.4% downside).
The 12-month forecast for IFF is moderately bullish. The base case (50% probability) sees the stock trading in the $78-$91 range, with gradual margin improvement and the divestiture progressing, leading to the analyst average target of $91.21. The bull case (25% probability) targets $91-$105, driven by faster-than-expected margin recovery and a favorable divestiture announcement. The bear case (25% probability) sees the stock falling to $59-$71 if revenue continues to decline and margins stall. The most likely scenario is the base case, with the stock appreciating toward $91 as earnings improve. Key assumptions include revenue stabilizing and operating margins reaching 10-11%.
IFF appears fairly valued relative to its own history but slightly overvalued versus industry peers. The current P/S ratio of 1.58x is below the 5-year average of approximately 2.5x, suggesting it is undervalued compared to its own past. However, it trades at a 32% premium to the specialty chemicals industry average P/S of 1.2x, indicating the market is paying a premium for its market leadership and turnaround potential. The forward P/E of 16.3x is reasonable for a company expected to grow earnings significantly, but it implies the market expects a successful recovery. Overall, the valuation is balanced and reflects cautious optimism.
IFF is a good buy for investors with a medium-term horizon who believe in the company's turnaround story. The stock offers 16.6% upside to the analyst average target of $91.21, supported by a Buy consensus from 18 analysts. The forward P/E of 16.3x is reasonable given expected EPS of $5.32, and the P/S of 1.58x is near the low end of its historical range, suggesting limited downside. However, the biggest risk is the ongoing revenue decline (-3.6% YoY), which could delay the earnings recovery. For risk-tolerant investors, the risk/reward is favorable; for conservative investors, waiting for evidence of revenue stabilization may be prudent.
IFF is best suited for a medium-term investment horizon of 12-24 months. The stock's beta of 0.94 indicates lower volatility than the market, making it less suitable for short-term trading. The dividend yield of 2.37% provides some income, but the payout ratio is negative (-113%), meaning the dividend is not fully covered by earnings. The company is in a turnaround phase, with the key catalyst (Food Ingredients divestiture) not expected until 2027. Long-term investors may benefit from the post-divestiture simplification, but near-term revenue weakness could cause volatility. A minimum holding period of 12 months is recommended to allow the margin recovery and divestiture progress to materialize.